Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Taking stock of the drug industry, from the lab to the medicine chest

March 10, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial The company is facing pressure to develop a new blockbuster obesity drug to follow up on its approved GLP-1 treatment Wegovy. By Elaine Chen STAT+ | Mineralys Therapeutics stock soars on blood pressure drug data The small drug developer said its therapy, lorundrostat, significantly reduced blood pressure in two different studies, giving the medicine a path to market. By Matthew Herper STAT+ | Opinion: How will the Center for Biologics Evaluation and Research change under RFK Jr.? A recent agency workshop on cell therapies and tissue-based products brought some surprises with potentially major implications. By Paul Knoepfler Adobe STAT+ | Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition The company used base editing to fix a mutation that drives a debilitating lung condition, alpha-1 antitrypsin deficiency, or AATD. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser